Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase

Biochemical Pharmacology

Volumn 71, Issue 10, 2006, Pages 1422-1434

  Ellis, A G ^a   Doherty, M M ^b   Walker, F ^c   Weinstock, J ^c   Nerrie, M ^c   Vitali, A ^c   Murphy, R ^c   Johns, T G ^c   Scott, A M ^c   Levitzki, A ^d   McLachlan, G ^e   Webster, L K ^a   Burgess, A W ^c   Nice, E C ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e Institute of Drug Technology   (Australia)

Author keywords

AG1478; EGFR receptor; Microphysiometer; Pharmacokinetics; Quinazoline; Tyrosine kinase inhibitor

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG SCREENING; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE; TUMOR CELL LINE;

ANIMALS; AREA UNDER CURVE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MICE; MOLECULAR STRUCTURE; PROTEIN-TYROSINE-PHOSPHATASE; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDINE; TYRPHOSTINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33646044696     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.01.020     Document Type: Article

References (62)

1. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J., et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12 (2003) 541-552
2. De Bono J.S., and Rowinsky E.K. Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br Med Bull 64 (2002) 227-254
3. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 2 (2001) 127-137
4. Kari C., Chan T.O., Rocha de Quadros M., and Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63 (2003) 1-5
5. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 56 (2000) 6550-6565
6. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
7. Tiseo M., Loprevite M., and Ardizzoni A. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr Med Chem Anti-Canc Agents 4 (2004) 139-148
8. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., and Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7 (2005) 301-311
9. Wels W., Biburger M., Muller T., Dalken B., Giesubel U., Tonn T., et al. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumour-specific targeting of cytotoxic effectors. Cancer Immunol Immunother 53 (2004) 217-226
10. Wells A. The epidermal growth factor receptor? A new target in cancer therapy. Signal 1 (2000) 4-10
11. Shaw J.P., Akiyoshi D.E., Arrigo D.A., Rhoad A.E., Sullivan B., Thomas J., et al. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem 266 (1991) 21118-21124
12. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 Suppl. 4 (2002) 2-8
13. Gosh S., Liu X.P., Zheng Y., and Uckun F.M. Rational design of potent and selective EGFR tryrosine kinase inhibitors as anticancer agents. Curr Cancer Drug Targets 1 2 (2001) 129-140
14. Bridges A.J. The rationale and strategy used to develop a series of highly potent, irreversible inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 6 (1999) 825-843
15. Powell T.J., Ben-Bassat H., Klein B.Y., Chen H., Shenoy N., McCollough J., et al. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Brit J Dermatol 141 (1999) 802-810
16. Shawver L.K., Slamon D., and Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1 (2002) 117-123
17. Morin M.J. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumour and anti-angiogenic agents. Oncogene 19 (2002) 6574-6583
18. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
19. Baselga J. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. Ann Oncol 13 (2002) 8-9
20. Shepherd F.A., Pereira J., Ciuleanu T.E., Tan E.H., Hirsh V., Thongprasert S., et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed) 22 14S (2004) 7022
21. Denny W. Irreversible inhibitors of the erbB family of protein tyrosine kinases. Pharmacol The 93 (2002) 253-261
22. Raymond E., Faivre S., and Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl. 1 (2000) 15-23
23. Nagane M., Narita Y., Mishima K., Levitzki A., Burgess A.W., Cavenee W.K., et al. Human glioblastoma xenografts overexpressing a tumour-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95 (2001) 472-479
24. Perera R.M., Narita Y., Furnari F.B., Gan H.K., Murone C., Ahlkvist M., et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11 (2005) 6390-6399
25. Chakravarti A., Chakladar A., Delaney M.A., Latham D.E., and Loettler J.S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62 (2002) 4307-4315
26. Solomon B., Hagekyriakou J., Trivett M.K., Stacker S.A., McArthur G.A., and Cullinane C. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumour effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 55 3 (2003) 713-723
27. Johnson D.H., Herbst R., Giaccone G., Schiller J., Natale R.B., Miller V., et al. ZD1839 ("Iressa") in combination with paclitaxel & carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals Oncol 13 Suppl. 5 (2002) Abstr 4680
28. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
29. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
30. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC) 267 (1995) 1782
31. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 36 (2003) 462-469
32. Lichtner R.B., Menrad A., Sommer A., Klar U., and Schneider M.R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 61 (2001) 5790-5795
33. Osherov N., and Levitzki A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur J Biochem 225 (1994) 1047-1053
34. Meylan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379 (1996) 645-648
35. Partik G., Hochegger K., Schörkhuber M., and Marian B. Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumour cells in vitro. J Cancer Res Clin Oncol 125 (1999) 379-388
36. Zhu X.F., Liu Z.C., Xie B.F., Li Z.M., Feng G.K., Yang D., et al. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 169 (2001) 27-32
37. Nagane N., Levitzki A., Gazit A., Cavanee W.K., and Huang H.J. Drug resistance of human glioblastoma cells conferred by a tumour specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase 3-like proteases. Proc Natl Acad Sci USA 95 (1998) 5724-5729
38. Lei W., Mayotte E.J., and Levitt L.M. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 19 (1999) 221-228
39. Busse D., Doughty R.S., Ramsey T.T., Russell W.E., Price J.O., Flanagan W.M., et al. Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1 independent of MAPK activity. J Biol Chem 275 10 (2000) 6987-6995
40. Johns T.G., Luwor R.B., Murone C., Walker F., Weinstock J., Vitali A.A., et al. Antitumour efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100 (2003) 15871-15876
41. Sugawa N., Ekstrand A.J., James C.D., and Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87 (1990) 8602-8606
42. Okimoto K., Rajewski R.A., Uekama K., Jona J.A., and Stella V.J. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) beta-cyclodextrins. Pharm Res 13 2 (1996) 256-264
43. Ueda H., Ou D., Endo T., Nagase H., Tomono K., and Nagai T. Evaluation of a sulfobutyl ether beta-cyclodextrin as a solubilizing/stabilizing agent for several drugs. Drug Dev Ind Pharm 24 9 (1998) 863-867
44. Loftsson T., and Brewster M.E. Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization. J Pharm Sci 85 (1996) 1017-1027
45. Davis M.E., and Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3 (2004) 10235
46. Walker F., Hibbs M.L., Zhang H.H., Gonez L.J., and Burgess A.W. Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line BaF/3. Growth Factors 16 (1998) 53-67
47. Whitehead R.H., Macrae F.A., St John D.J., and Ma J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J Natl Cancer Inst 74 (1985) 759-765
48. Ellis A.G., Nice E.C., Weinstock J., Levitzki A., Burgess A.W., and Webster L.K. High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma. J Chromatogr B 754 (2001) 193-199
49. Waynforth H.B., and Flecknell P.A. Experimental and surgical technique in the rat. 2nd ed. (1994), Academic press Ltd., London
50. Jungbluth A.A., Stockert E., Huang H.J., Collins V.P., Coplan K., Iversen K., et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 100 (2003) 639-644
51. McConnell H.M., Owicki J.C., Parce J.W., Miller D.L., Baxter G.T., Wada H.G., et al. The cytosensor microphysiometer: biological applications of silicon technology. Science 257 (1992) 1906-1912
52. Lui K.E., Panchal A.S., Santhanagopal A., Dixon S.J., and Bernier S.M. Epidermal growth factor stimulates proton efflux from chondrocytic cells. J Cell Physiol 192 (2002) 102-112
53. Lauffenburger D.A., Oehrtman G.T., Walker L., and Wiley H.S. Real-time quantitative measurement of autocrine ligand binding indicates that autocrine loops are spatially localized. Proc Natl Acad Sci USA 95 (1998) 15368-15373
54. Owicki J.C., Parce J.W., Kercso K.M., Sigal G.B., Muir V.C., Venter J.C., et al. Continuous monitoring of receptor-mediated changes in the metabolic rates of living cells. Proc Natl Acad Sci USA 87 (1990) 4007-4011
55. Chan S.D., Antoniucci D.M., Fok K.S., Alajoki M.L., Harkins R.N., Thompson S.A., et al. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3. J Biol Chem 270 (1995) 22608-22613
56. Walker F., Orchard S.G., Jorissen R.N., Hall N.E., Zhang H.H., Hoyne P.A., et al. CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor. J Biol Chem 279 (2004) 22387-22398
57. Smith E.R., Hadidian Z., and Mason M.M. The single- and repeated-dose toxicity of dimethylsulfoxide. Ann NY Acad Sci 141 (1967) 96-109
58. McKillop D., Partridge E.A., Kemp J.V., Spence M.P., Kendrew J., Barnett S., et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 4 4 (2005) 641-649
59. Fredriksson A., Johnstrom P., Thorell J.O., von Heijne G., Hassan M., Eksborg S., et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 65 (1999) 165-174
60. ®). Oncologist 10 (2005) 579-589
61. Twombly R. Failing survival advantage in crucial trial, future of Iressa in jeopardy. J Natl Cancer Inst 97 (2005) 249-250
62. Fuster L.M., and Sandler A.B. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer 6 Suppl. 1 (2004) S24-S29